The use of permuted pmel T cells is a classic TCR-T treatment that uses genetic engineering techniques to introduce a TCR gene capable of specifically recognizing glycoprotein 100, a melanoma antigenic epitope, into CD8+ T cells, followed by amplification, after which it is infused back into the body. This evidence concerns the gene CD8A and melanoma.